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Abstract 25 
Background & aims: Adequate supply of arachidonic (ARA) and docosahexaenoic (DHA) 26 
acids is essential for brain development, and extremely preterm infants may be at risk of 27 
deficiency. Current levels of ARA and DHA given to extremely preterm infants and the 28 
amounts available for accretion have not been established, although recent evidence suggests 29 
DHA intake is at a level likely to lead to severe deficits. This study quantified the omega-6 30 
and omega-3 polyunsaturated fatty acid (PUFA) intakes from all sources in the first six weeks 31 
of life of preterm infants in standard care. In addition, the relationship between blood levels 32 
of circulating cytokines and PUFAs was explored. 33 
Methods: Single centre longitudinal study with omega-6 and omega-3 PUFA intake data 34 
analysed from all sources for 17 infants born < 28 weeks gestation. At six weeks of age the 35 
infants’ whole-blood fatty acid levels were measured along with a range of cytokines and 36 
chemokines analysed by Luminex® multiplex array.  37 
Results: ARA intake was significantly below international recommendations in weeks 1-5 38 
(all p < 0.05), and DHA intake was significantly below recommendations in week 1 (p < 39 
0.0001). The amounts of ARA and DHA available for accretion were significantly below 40 
estimated accretion rates in all weeks (all p < 0.001). Mean ARA and DHA intakes were 41 
correlated  with their respective blood levels (r = 0.568, p = 0.017 and r = 0.704, p = 0.002). 42 
There were  significant relationships between MIP-1β and blood DHA levels (rs = 0.559, p = 43 
0.02) and between RANTES and  omega-6:omega-3 PUFA ratio (rs = -0.498, p = 0.042). 44 
Conclusions: This study establishes that extremely preterm infants receive insufficient intakes 45 
of ARA and DHA. Moreover, blood fatty acid levels may provide a useful measure of intake, 46 
where establishing sufficient consumption could have clinical importance. There may also be 47 
important interactions between long-chain PUFA status and markers of inflammation, which 48 
requires further study. 49 
3 
 
Keywords: arachidonic acid, docosahexaenoic acid, breast milk, preterm infants, 50 
inflammation 51 
 52 
1. Introduction  53 
The brain is enriched in arachidonic (ARA) and docosahexaenoic (DHA) acids, long-chain 54 
polyunsaturated fatty acids (LC-PUFAs) of omega-6 and -3 series, respectively, with both 55 
essential for optimum brain development [1]. Fetal demand for ARA and DHA is high, 56 
especially in the last trimester, the period of maximal brain growth [2]. Prior to birth ARA 57 
and DHA are provided by placental transfer, and thereafter from breast milk and/or infant 58 
formula [3]. Although preterm infants are capable of synthesising ARA from linoleic acid 59 
(LA) and DHA from α-linolenic acid (ALA) the conversion is extremely limited [4]. 60 
Moreover, analyses of human infant autopsy tissue suggests that preterm infants are 61 
especially at risk of the developing fatty acid imbalances in the brain and retina in response to 62 
low ARA and DHA intake [5].  63 
 64 
The Committee on Nutrition of the European Society for Paediatric Gastroenterology, 65 
Hepatology, and Nutrition (ESPGHAN) have set recommendations for enteral nutrition in 66 
preterm infants for LA, ALA, ARA, DHA and eicosapentaenoic acid (EPA) [6]. However, 67 
these guidelines do not consider the greater requirements needed to compensate for early 68 
nutritional deficits and malabsorption or indeed reflect in utero accretion rates [7]. There are 69 
a range of estimated values for in utero ARA and DHA accretion rates depending on the 70 
background assumptions made [2, 8, 9]; however, the most recent estimates for accretion 71 
rates of ARA and DHA in the last trimester are 212 and 45 mg/kg/day, respectively [2], 72 
which are far higher than the ESPGHAN recommended intakes for ARA and DHA of 18 to 73 
42 and 12 to 30 mg/kg/day, respectively [6]. 74 
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 75 
To help to identify the optimum feeding regimes needed for extremely preterm infants to 76 
meet these recommendations and establish the potential deficits in ARA and DHA compared 77 
to in utero accretion rates it is necessary to quantify actual omega-6 and omega-3 PUFA 78 
intake from all sources. A recent study suggests DHA intake is at a level likely to lead to 79 
severe deficits [7]; however, the breast milk fatty acid composition was not directly measured 80 
in this study, nor importantly was ARA intake evaluated. This present study therefore extends 81 
these important initial observations by directly quantifying the omega-6 and omega-3 PUFA 82 
intake from all sources in extremely preterm infants born at < 28 weeks gestational age. Since 83 
the LC-PUFA composition of maternal milk varies widely [10], and ARA and DHA levels 84 
decline over time in the transition from colostrum to mature milk [11], the fatty acid 85 
composition of maternal breast milk was longitudinally measured at six time-points over the 86 
study. The levels of intake are presented as absolute intake levels of LA, ARA, ALA, EPA 87 
and DHA and levels of ARA and DHA available for accretion, which are calculated from the 88 
metabolizable levels and the amount endogenously synthesized, as recommended [7].  In 89 
addition, whole-blood fatty acid levels measured in week six  were examined as potential 90 
useful biomarkers for fatty acid intake. 91 
 92 
In the second part of the study, the relationship between blood LC-PUFA levels and markers 93 
of inflammation in the preterm infants was explored. Infection and inflammatory conditions 94 
are a major source of morbidity and mortality in premature infants and the vulnerability of 95 
the preterm infant to infection is well-described. Therefore, a robust immune response is 96 
essential for survival. In the neonate the blood brain barrier is more permeable than in the 97 
adult, and cytokines may gain direct access to the brain from the circulation [12] and pro-98 
inflammatory cytokines have been shown to exert a toxic effect on the developing brain: [13]. 99 
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DHA and EPA have well characterised anti-inflammatory properties [14] and the omega-6 to 100 
omega-3 PUFA balance has been shown to be  a predictor of neonatal morbidities in preterm 101 
infants [15]. The aim of this analysis was to identify if there were any relationships between 102 
potential biomarkers of inflammation and blood omega-3 and -6 PUFA levels. 103 
 104 
2. Materials and methods 105 
2.1 Participants 106 
This was a monocentric longitudinal study conducted in a tertiary, surgical neonatal unit in 107 
London, U.K. Participation was offered to all infants either inborn or transferred into the unit 108 
within 3 days of birth at < 28 weeks gestation. Infants with major congenital abnormalities, 109 
life-limiting conditions, from families who were not able to access the study information in 110 
English, or with mothers who were < 18 years of age at the start of the study were excluded. 111 
The West of Scotland Research Ethics Committee gave ethical approval, host site approval 112 
was confirmed by the Hospital’s Joint Research & Enterprise Office and the University of 113 
Roehampton Ethics Committee. All mothers gave informed consent and the study was 114 
conducted according to the Declaration of Helsinki guidelines. 115 
 116 
2.2 Study design 117 
Intensive care and high dependency days were recorded as defined in SEND (standardised 118 
electronic neonatal database) for each infant. Daily weights, volumes of maternal, banked and 119 
formula milk consumed and parenteral lipid administered were recorded prospectively.  120 
 121 
2.3 Determination of fatty acids in breast milk 122 
Breast milk samples (0.5 – 5 mL) were collected at six time points in order to allow 123 
colostrum, transitional and mature milk to be sampled. For colostrum and transitional milk, 124 
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hand expression was used and for mature milk machine expression (Axifeed Fisio R, 125 
Orthofix Ltd, UK) was used.  The time points were: sample 1, day 0 - 4; sample 2, day 5 - 9; 126 
sample 3, day 10 - 15; sample 4, day 16 - 23; sample 5, day 24 - 33 and sample 6, day 34 - 127 
42. Where possible, expressions from more than one time-point on the day were pooled to 128 
allow for differences in milk expression during the course of 24 hours. All samples were 129 
frozen at -700C on the day of collection and analysed within two months.  130 
 131 
The initial lipid extraction was from 0.5 mL of milk using the Bligh and Dyer method [16]. 132 
Tricosanoic acid was added at 0.5 mg/mL as an internal standard. Fatty acid methyl esters 133 
were prepared  and analyzed by gas chromatography coupled with flame ionisation detector 134 
(Agilent Technologies, 7820A) using an OmegawaxTM column (30 m x 0.2 µm x 0.2 mm i.d., 135 
Sigma-Aldrich, UK), as described previously [17].  136 
 137 
2.4 Whole blood fatty acid analysis 138 
A drop of whole-blood for fatty acid analysis was collected from the infants by heel prick 139 
(about 20 µL) during the last study week and analysed as described previously [17]. Briefly, 140 
the samples were collected onto Whatman filter paper impregnated with 2,6-bis(1,1-141 
dimethylethyl)-4-methylphenol (butylated hydroxytoluene, BHT), at 50 mg / 100 mL in 142 
ethanol. The paper was air-dried for one hour and then wrapped in foil and sealed in 143 
polythene bag  and kept at -80°C until analysis, which was typically within two weeks.  144 
 145 
2.5 Blood cytokine and chemokine analysis 146 
The blood samples for cytokine and chemokine analysis were collected in parallel with the 147 
samples for fatty acid analysis. Between 0.4 - 0.6 mL was collected into a SST serum 148 
separator gel microtainer. The sample stood at room temperature for 30 min, centrifuged at 149 
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3000 rpm for 10 min, and the serum frozen at -70°C. A bead-based multiplex assay 150 
(Luminex®, R&D systems) was used according to the manufacturer’s instructions.  The pro-151 
inflammatory markers analysed were: tumour necrosis factor α (TNFα), Interleukin 1β (IL-152 
1β), Interleukin 2 (IL-2), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 8 (IL-8), other 153 
inflammatory proteins: Interferon γ (IFN-γ), Granulocyte-macrophage colony-stimulating 154 
factor (GMCSF), Granulocyte colony stimulating factor (GCSF), Monocyte chemoattractant 155 
protein 1 (MCP-1), Macrophage inflammatory protein-1β (MIP-1β)  and Regulated on 156 
Activation, Normal T Expressed and Secreted (RANTES). The anti-inflammatory markers 157 
were: Interleukin 10 (IL-10), Interleukin 1 receptor antagonist IL- 1ra), Interleukin 4 (IL-4), 158 
Interleukin 17 (IL-17). The Luminex® Performance Human Cytokine Panel A was used, and  159 
samples were read using the Luminex® Flexmap 3D analyser. All samples were analysed on 160 
the same plate. 161 
 162 
2.6 Quantification of LA, ALA, ARA, EPA and DHA intake 163 
The total LA, ALA, ARA, EPA and DHA intake from all sources was measured. Milk and 164 
parenteral lipid intake was recorded. Fatty acid intakes from formula milk were calculated 165 
based on manufacturer’s published values, and milk samples of the infants’ majority intake 166 
were analysed at six time points within the first six weeks of life. These values were 167 
compared with ESPGHAN guidelines [6]. 168 
 169 
2.7 Estimation of ARA and DHA available for metabolism and accretion 170 
Estimations of ARA and DHA available for metabolism and accretion were based on 171 
previously published assumptions [7]. The amount of ARA and DHA available for 172 
metabolism was calculated based on intestinal absorption of rates of 80% for both PUFAs 173 
[18]. Absolute ARA and DHA synthesis in preterm infants at 1 month old fed LC- PUFAs 174 
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has been reported to be 27 ± 4 and 13 ± 4 mg/kg/day, respectively [19]. In our calculations 175 
values of 27 and 13 mg/kg/day for ARA and DHA synthesis were set when total energy 176 
intake was ≥ 100 kcal/kg/day and 9 and 4 mg/kg/day when intake was < 100 kcal/kg/day, 177 
respectively. The amounts of ARA and DHA available for accretion were calculated from the 178 
sum of metabolizable and endogenously synthesized values. These values were compared 179 
with published estimated accretion rates [2]. 180 
 181 
2.8 Statistical analysis 182 
The results are reported according to STROBE guidelines [20]. Descriptive statistics were 183 
calculated for infant and maternal characteristics. Unless otherwise stated the results are 184 
presented as means (SD). Groups were compared by one-way ANOVA followed by the 185 
Tukey post hoc test. Fatty acid values were compared with published guidelines by one 186 
sample t-test. The cytokine and chemokine data were not normally distributed and are 187 
presented as median values (IQR) and correlations were evaluated using the two-sided 188 
Spearman test. This is an exploratory study and in all analyses p < 0.05 was considered 189 
statistically significant and there was no adjustment of p values for multiple comparisons to 190 
avoid Type-II errors, as recommended [21]. Statistical analysis was performed using either 191 
SPSS (IBM SPSS Inc., v.20.0) or GraphPad Prism (Version 6.07, GraphPad Software Inc.) 192 
Figures were prepared using GraphPad Prism. 193 
 194 
3. Results 195 
3.1. Participant characteristics 196 
Participant flow is shown in Figure 1, where it can be seen that 24 preterm infants were 197 
recruited. 17 completed the study, all of whom were included in the final analyses. Maternal 198 
and infant clinical characteristics and infant clinical outcomes are shown in Table 1. The 199 
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infants’ mean number of days to reach full feeds (150 mL/kg/day) was 19 (9.2) days, and the 200 
infants had a mean of 18 (9.1) days of parenteral nutrition support.  201 
 202 
3.2 Wide variability of maternal breast milk fatty acid content over the first six weeks 203 
The mean omega-6 and omega-3 PUFA concentrations of maternal breast milk are shown in 204 
Table 2. Over the six weeks of the study there were significant differences in the mean ARA 205 
and DHA content as determined by repeated measures one-way ANOVA (F(2.046, 32.74) = 206 
119.3, p < 0.0001 and F(2.120, 33.92) = 42.13, p < 0.001), respectively. A Tukey post-hoc 207 
test revealed that the mean ARA content significantly decreased over the period of the study 208 
(p < 0.05), with the mean values of sample 6 comprising only 65% of sample 1. Similarly, 209 
there were also significant decreases in the DHA content over the study (p < 0.05), with 210 
sample 6 content only 64% of the value of sample 1. There was wide variability in ARA and 211 
DHA content between the individual mother’s milks, as shown in Figure 2. There were no 212 
significant differences in the content of any of the other omega-6 PUFAs over the study. 213 
Although there were significant differences in the ALA between the groups (F(3.093, 49.49) 214 
= 3.521, p < 0.02), there were no observable trends across the study. There were also 215 
significant differences in the EPA concentrations (F(2.659, 42.54) = 3.298, p < 0.03); 216 
however, many of the values were at the limit of quantification and these results should be 217 
interpreted with caution.   218 
 219 
3.3 LA, ARA, ALA, EPA and DHA intake levels in the preterm infants 220 
The week-by-week total mean intakes of LA, ARA, ALA, EPA and DHA from both 221 
parenteral and enteral sources are given in Table 3, along with the metabolizable amounts 222 
(parenteral and enteral intake available for absorption) and amount of ARA and DHA 223 
available for accretion (metabolizable plus endogenously synthesized amounts). There were 224 
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significant differences in LA intake across the study (F (5, 96) = 8.204, p < 0.0001), with 225 
intakes significantly lower in weeks four, five and six, than weeks one and two (all at p < 226 
0.05). LA intake was significantly below the minimum ESPGHAN recommended intake 227 
levels of 385 mg/kg/day in week 6 (t = 2.9782, p = 0.009) [6]. ALA intake significantly 228 
differed across the study (F (5, 96) = 9.392, p < 0.0001), with intakes significantly lower in 229 
weeks four, five and six, than weeks one and two (all at p < 0.05). ALA was significantly 230 
below the ESPGHAN guidelines of > 55 mg/kg/day in week six (t = 6.2188, p < 0.0001). The 231 
mean intake of ARA differed across the study (F (3.318, 53.09) = 14.52, p < 0.0001) with 232 
significant increases from the first to the second week (p < 0.05) and then remained at similar 233 
levels for the remainder of the study. The ARA intake was significantly below the 234 
ESPGHAN minimum intake levels of 18 mg/kg/day in weeks one to five (all p < 0.05). DHA 235 
intake differed across the study (F (3.863, 61.81) = 7.933, p < 0.0001) increasing 236 
significantly from the first to the second week (p < 0.05) and then remaining at similar levels. 237 
DHA was significantly below the minimum ESPGHAN intake guidelines of 12 mg/kg/day in 238 
week one only (t = 16.0801, p < 0.001). EPA intake levels were not significantly different 239 
across the study, and were within EPSGHAN recommended levels.  240 
 241 
3.4 The ARA and DHA content available for accretion leads to deficits in the preterm infants 242 
The mean ARA and DHA available for accretion significantly increased between the first and 243 
second weeks, (F(5, 96) = 9.415, p < 0.001 and F(5, 96) = 6.760, p < 0.001, respectively), 244 
and then both remained at about these levels for the remaining period of the study (Figure 3). 245 
These values were all significantly below the values estimated for ARA and DHA provided 246 
in utero (all values p < 0.0001). The values for the cumulative mean ARA and DHA deficits 247 
produced over the six weeks of the study were calculated by successively adding the weekly 248 
deficits derived from the individual daily deficits, and are shown in Figure 4. The ARA 249 
11 
 
values at the end of the 6 weeks represented 13.5% of the levels that should have been 250 
provided in utero, whereas for DHA the value was 36.6%. To compensate for these deficits 251 
an additional 183.4 mg/kg/day of ARA and 28.5 mg/kg/day of DHA available for accretion 252 
would be required to match levels provided in utero.  253 
 254 
3.5 Relationships between intake and whole-blood fatty acid levels 255 
The mean (SD) whole-blood levels of the omega-6 and omega-3 PUFAs of the preterm 256 
infants at six weeks and the mean intakes of LA, ARA, ALA, EPA and DHA are shown in 257 
Table 4. The mean haemoglobin level in week six was 110.9 g/L (15.1 g/L), and none of the 258 
infants were considered clinically anaemic. Blood samples were not taken until week six to 259 
limit complications due to the number of transfusions given. The mean number of 260 
transfusions over the study was 6.4 (3.4), with the mean number in week one 1.8 (1.3), week 261 
two, 1.3 (1.2), weeks three and four, 2.2 (1.5) and weeks five and six, 1.1 (0.9). The strength 262 
of relationship between mean intake levels and blood fatty acid levels was estimated by 263 
Pearson product-moment correlation coefficient. There were significant positive correlations 264 
between mean DHA intake and blood DHA levels (r = 0.704, p = 0.002), mean ARA intake 265 
and blood ARA levels (r = 0.568, p = 0.017) and mean EPA intake and blood EPA levels (r = 266 
0.572, p = 0.016). There were no significant correlations with LA or ALA levels and their 267 
respective blood levels. 268 
 269 
3.6 Relationships between whole-blood DHA and cytokine and chemokine levels  270 
In the final part of the study the relationship between the whole-blood levels DHA levels and 271 
a range of pro- and anti-inflammatory cytokine and chemokines was explored at six weeks.  272 
As the cytokine and chemokine values were not normally distributed relationships were 273 
estimated using Spearman’s rank order tests. There were significant correlations between 274 
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MIP-1β and DHA (rs = 0.559, p = 0.02) and MIP-1β and AA/DHA ratio (rs = -0.690, p = 275 
0.002), as well as between MIP-1β and the omega-6:omega-3 PUFA ratio (rs= -0.716, p = 276 
0.001). The omega-6:omega-3 PUFA ratio was also negatively correlated with RANTES (rs = 277 
-0.498, p = 0.042). There were no significant correlations with any of the other cytokines or 278 
chemokines. 279 
 280 
4. Discussion 281 
This is the first study to quantify the omega-6 and omega-3 PUFA intake from all sources of 282 
extremely preterm infants born at less than 28 weeks over the first six weeks of care. From 283 
these results it can be seen that the infants were receiving intakes below ESPGHAN 284 
guidelines for LA, ALA, ARA and DHA and furthermore, the intakes of ARA and DHA 285 
were well below estimated in utero accretion rates. Importantly, these deficits occurred in 286 
spite of the infants receiving maternal breast milk from an early stage, and may be due to the 287 
wide variability in ARA and DHA content of the breast milk between the mothers, as has 288 
been shown by others [10]. These results are of clinical importance as low ARA and DHA 289 
levels in preterm infants may adversely affect neural development and health outcomes [22].  290 
 291 
It has been suggested that the smallest infants at threshold viability and birth weight have the 292 
greatest relative deficit in LC-PUFAs, due to the low level of provision of preformed ARA 293 
and DHA and limited efficiency in the conversion of LA and ALA to the LC-PUFAs [4]. 294 
Much research has been focused on the effects of supplementing preterm infants with DHA 295 
and ARA, with heterogeneous result. These mixed results may be due to a range of 296 
methodological issues, but also importantly due to a lack of recruitment of sufficient numbers 297 
of very small, very immature infants [4]. Furthermore, most supplementation trials have 298 
attempted to supplement human or formula milk to reach levels typical of the ‘average’ DHA 299 
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in human milk for term infants. During pregnancy there is a preferential transfer of ARA and 300 
DHA across the placenta [23], which is very different to the supply available in term breast 301 
milk. 302 
 303 
Recommendations for enteral nutrient intake aim to provide levels needed to achieve growth 304 
similar to fetal growth and satisfactory functional development [6]. However, these 305 
recommendations do not consider the potential additional needs required to compensate for 306 
early nutritional deficits and it may therefore be more appropriate to consider intake levels 307 
compared to in utero accretion rates. In the present study, therefore in addition to quantifying 308 
the absolute intake of omega-6 and omega-3 PUFAs and comparing these to ESPGHAN 309 
recommendations, the amounts of ARA and DHA available for metabolism and accretion 310 
were also calculated, based on previously published assumptions [7]. In both of the analyses 311 
the results confirm the previous observation that current feeding practices provide levels of 312 
DHA intake that are likely to lead to severe deficits; however, the present results also 313 
provides the first evidence that deficits in ARA are likely to be of an even greater magnitude. 314 
The effects of these intake levels were investigated on whole blood fatty acid levels, as a 315 
surrogate marker for whole body stores.  316 
 317 
Lower blood levels of ARA and DHA are associated with increased risk of neonatal 318 
morbidities in preterm infants [15]. It is therefore important to establish whether the low level 319 
of intake found in the present study is reflected in the blood levels. However, analysis of 320 
blood levels in this patient group is complicated due to the number of transfusions they 321 
typically receive. For this reason whole-blood fatty acid analysis was not undertaken until 322 
week six of the study and it must be acknowledged that even by this time only two infants did 323 
not receive transfusions in the two weeks preceding the sampling. However, only three 324 
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infants received more than one transfusion and significant correlations were found for ARA, 325 
DHA and EPA intake and blood levels, suggesting whole-blood samples may provide useful 326 
clinical information, even in extremely preterm infants.  327 
 328 
As blood levels were not taken until week six it was not possible to assess whether the level 329 
of intake led to decreases in LC-PUFA levels over the study and comparisons must be made 330 
to published values. Martin and co-workers report significant rapid declines in DHA and 331 
ARA composition in preterm infants after birth [15]. The DHA values reported in their study 332 
at week four are similar to those observed in the present study at week six, consistent with a 333 
need for DHA supplementation. Whereas the values we report for ARA are similar to those 334 
shown at week one, and are therefore not consistent with deficiency. Similarly, compared to 335 
the ARA and DHA values reported in a recent study by Baack and co-workers, the results in 336 
the present study do not suggest a deficiency [24].  337 
 338 
However, comparisons with published values are complicated due the results being expressed 339 
as percent composition values based on area normalisation. With this approach the 340 
composition values do not provide absolute concentrations and are strongly interdependent 341 
and vary depending on the number of fatty acids analysed. Omissions or additions of fatty 342 
acids in the analyses will affect the values of the other fatty acids reported. This and other 343 
methodological differences may explain the apparent anomaly with blood values not 344 
apparently indicative of deficiency. These types of difficulties comparing whole-blood fatty 345 
acid results between studies have been reported by others [25]. Therefore, overall with data 346 
based on the single whole-blood samples taken at six weeks it is not possible to confirm that 347 
the DHA and ARA intake was insufficient to compensate for in utero provision; however, 348 
with the low levels of intake and equivocal nature of the comparisons to other studies 349 
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supplementation of extremely preterm infants with additional preformed DHA and ARA may 350 
be prudent.     351 
 352 
The results show that assuming an intestinal absorption rate of 80% additional intakes of 230 353 
mg/kg/day of ARA and 36 mg/kg/day of DHA would be needed to provide levels similar to 354 
those found in utero. Whilst this level of DHA intake has been achieved in intervention 355 
studies, ARA supplementation is typically either given at doses similar to those of DHA, or 356 
not at all [26]. However, a recent study reported beneficial effects on blood fatty acid status 357 
and psychomotor development of extremely preterm infants provided with ARA at twice the 358 
levels of DHA [27]. Future trials should seek to identify the effects of higher levels of ARA 359 
intake which have been identified from enteral intake requirements. 360 
 361 
Most supplementation trials to date have used the enteral route once feeds are established. In 362 
our cohort of extremely small infants, the mean duration to reach full feeds was 19 days, 363 
which is representative of reported time to full feed intervals for infants of this gestation [28]. 364 
This leaves an important 2-3 week gap in which reduced amounts of preformed ARA or 365 
DHA are available. Newer parenteral lipid formulations which include fish oils as their 366 
source of LC-PUFAs are potentially available for use in neonates. There is encouraging 367 
evidence for their safety and tolerance to date [28]. However, long-term parenteral nutrition 368 
is not the norm for the extremely preterm infant, and adequate supplementation once enteral 369 
feeds are established remains a concern.   370 
 371 
Finally, the relationship between circulating cytokine and chemokines and blood PUFA 372 
levels was investigated. This exploratory part of the study identified some potential 373 
relationships between blood omega-6 and omega-3 PUFA status and markers of 374 
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inflammation. The most consistent observations were seen with MIP-1β. MIP-1β is a 375 
chemotactic cytokine produced by macrophages, dendritic cells and lymphocytes and has 376 
chemotactic and pro-inflammatory effects, but can also promote homeostasis [29]. Significant 377 
positive correlations were shown between MIP-1β and DHA, with negative correlations 378 
between MIP-1 β and the ARA/DHA ratio, as well as between MIP-1 β and omega-6/omega-379 
3 PUFA ratio. These data suggest that as the omega-3 PUFA status increases, the infant’s 380 
ability to produce MIP-1β increases to that seen in a well term infant [30]. The omega-381 
6:omega-3 PUFA ratio was also negatively correlated with RANTES.  RANTES is a 382 
chemoattractant for monocytes, memory T-helper cells and eosinophils  [31]. Plasma 383 
RANTES levels are significantly lower in preterm infants with sepsis, disseminated 384 
intravascular coagulation and necrotising enterocolitis (NEC) [31]. These data suggest that a 385 
normal (as opposed to a low) level of RANTES is seen with higher omega-3 PUFA status. 386 
Overall, these data are suggestive of interactions between LC-PUFA status and markers of 387 
inflammation; however, further research with larger numbers studied longitudinally is 388 
required to confirm these observations. 389 
 390 
Important strengths of this study are that it was conducted at a neonatal centre which is also a 391 
surgical centre, and consequently infants with a wide range of conditions were included, and 392 
the milk fatty acid composition was measured at six time-points, so the subtle changes in the 393 
fatty acid profile over time were identified. Moreover, the omega-6 and omega-3 PUFA 394 
intake was quantified from all sources, and importantly the amount of ARA available for 395 
accretion was quantified for the first time. Blood fatty acid status was measured by a 396 
validated dried blood spot method, which is preferable for the assessment of circulating fatty 397 
acid fractions in preterm infants [24]; however, as noted above, blood fatty acid levels were 398 
only assessed at one time-point, six weeks. Furthermore, the large number of transfusions 399 
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received by some of the infants in this study may constitute a source of LC-PUFAs, which 400 
was not considered in the analysis. This study was conducted on extremely preterm infants, 401 
and therefore the results may not be applicable to infants born at a later gestational age; 402 
however, as information on this group is underrepresented in the literature this focus should 403 
be considered a strength of the study. It must be acknowledged that the study was only 404 
conducted at one site on a small number of infants; however, the nature and extent of the low 405 
DHA intake is consistent with results reported by others [7], suggesting the observations of 406 
low levels of DHA and ARA intake are applicable to other sites in the UK and across Europe. 407 
The results do however need to be confirmed by further research on a larger number of 408 
infants at other sites. Finally, a number of assumptions were used in calculating levels of 409 
ARA and DHA available for accretion; however, these assumptions were based on previous 410 
literature [7].  411 
 412 
The results indicate that omega-6 and omega-3 PUFA intake in extremely preterm infants 413 
receiving standard care is likely to lead to deficits in ARA and DHA. These results confirm 414 
and extend previous observations that current parenteral and enteral nutritional practices for 415 
the extremely preterm infant are likely to fall below the levels of LC-PUFAs provided in 416 
utero. There is growing evidence of the importance of optimising ARA and DHA provision 417 
postnatally not only for brain function, but also to potentially reduce the morbidity and 418 
mortality from conditions such as NEC, bronchopulmonary dysplasia (BPD) and retinopathy 419 
of prematurity (ROP) [4] and the present results highlight the need for supplementing preterm 420 
infants with preformed ARA and DHA. Furthermore, the positive correlations between intake 421 
of ARA, DHA and EPA and blood levels suggests preterm infants are responsive to different 422 
levels of intake, and that measuring blood levels may provide a useful clinical marker of 423 
sufficiency. 424 
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Figures Legends and Tables 522 
Figure 1 Flow of participants through the study 523 
 524 
Figure 2 (A) ARA and (B) DHA breast milk content from individual mothers. Sample 1, days 525 
0 - 4; sample 2, days 5 - 9; sample 3, days 10 - 15 sample 4, days 16 - 23; sample 5, days 24 - 526 
33 and sample 6, days 34 - 42 527 
 528 
Figure 3 (A) ARA and (B) DHA available for metabolism (i.e. parenteral and absorbed) and 529 
available for accretion (i.e. metabolizable and endogenously synthesized) for the 17 infants. 530 
Values expressed as mean (SD). Estimated ARA and DHA in utero accretions rates of 212 531 
and 45 mg/kg/day, respectively, are shown for reference. 532 
 533 
Figure 4. Cumulative (A) ARA and (B) DHA deficits of the 17 infants over the 6 weeks of 534 
the study compared to estimated in utero accretion rates. The cumulative deficits were 535 
calculated based on estimated in utero accretion rates of 212 and 45 mg/kg/day for ARA and 536 
DHA, respectively using previously published assumptions [7].  537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
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Table 1. Clinical characteristics and clinical outcomes of the 17 preterm infants born at < 28 547 
weeks gestational age  548 
Clinical characteristics Mean (SD) / number (%) 
Maternal age (yr) 31.8 (6) 
Antenatal steroid treatment 14 (82) 
Pregnancy complications  
            Pre eclampsia 1 (6) 
            Chorioamnionitis 6 (35) 
            Antepartum haemorrhage 6 (35) 
            Pre-labour rupture of membranes 3 (18) 
            Multiple pregnancy 2 (12) 
Gestational age (weeks) 25.3 (1.1) 
Gender, boys 9 (53) 
Birth weight (g) 770 (135) 
Birth weight z score 0.12 (0.45) 
Clinical outcomes  
PDA 13 (76) 
NEC, Bell’s stage 2 and above 2 (12) 
IVH grade 3 or 4 2 (12) 
PVL 1 (6) 
Sepsis requiring 5 days antibiotic treatment 16 (94) 
ROP requiring laser therapy 5 (29) 
CLD  
            Oxygen therapy at 28 days of life 17 (100) 
            Non-invasive respiratory support at 6 weeks of age 9 (53) 
24 
 
Abbreviations: PDA, patent ductus arteriosus; NEC, necrotising enterocolitis; IVH, 549 
intraventricular haemorrhage; PVL, peri-ventricular leukomalacia, ROP, retinopathy of 550 
prematurity, and CLD, chronic lung disease. 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
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Table 2. Mean (SD) omega-3 and omega-6 PUFA content of maternal breast milk of 17 573 
mothers of extremely preterm infants1 574 
 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
18:2n-6 
(LA) 
1.601 
(0.302) 
1.493 
(0.269) 
1.483 
(0.370) 
1.665 
(0.266) 
1.583 
(0.330) 
1.611 
(0.346) 
18:3n-6 0.018 
(0.006) 
0.019 
(0.006) 
0.020 
(0.007) 
0.018 
(0.007) 
0.018 
(0.006) 
0.020 
(0.009) 
20:2n-6 0.043 
(0.012) 
0.046 
(0.010) 
0.049 
(0.013) 
0.046 
(0.011) 
0.052 
(0.009) 
0.047 
(0.011) 
20:3n-6 0.059 
(0.014) 
0.057 
(0.012) 
0.059 
(0.013) 
0.059 
(0.017) 
0.061 
(0.016) 
0.066 
(0.022) 
20:4n-6 
(ARA) 
0.151 
(0.034) 
0.137 
(0.031) 
0.127 
(0.031) 
0.116 
(0.033) 
0.107 
(0.033) 
0.098 
 (0.033) 
22:4n-6 0.024 
(0.008) 
0.030 
(0.011) 
0.027 
(0.007) 
0.028 
(0.013) 
0.026 
(0.009) 
0.029 
(0.012) 
18:3n-3 
(ALA) 
0.107 
(0.026) 
0.101 
(0.026) 
0.097 
(0.022) 
0.094 
(0.018) 
0.104 
(0.026) 
0.118 
(0.027) 
20:3n-3 0.014 
(0.009) 
0.018 
(0.009) 
0.016 
(0.006) 
0.018 
(0.010) 
0.014 
(0.008) 
0.016 
(0.010) 
20:5n-3 
(EPA) 
0.006 
(0.007) 
0.006 
(0.008) 
0.010 
(0.009) 
0.009 
(0.007) 
0.013 
(0.005) 
0.013 
(0.005) 
22:6n-3 
(DHA) 
0.123 
(0.051) 
0.110 
(0.051) 
0.103 
(0.048) 
0.096 
(0.045) 
0.088 
(0.041) 
0.079 
(0.041) 
1 Results are expressed in mg/mL 575 
 576 
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Table 3. Mean (SD) omega-6 and omega-3 PUFA intakes of the 17 preterm infants for each 577 
week of the study (mg/kg/day) 578 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
Parenteral and enteral intakes 
LA 670.1 
(249.5) 
798.2 
(365.9) 
447.7 
(377.5) 
366.4 
(294.5) 
349.7 
(233.8) 
306.7 
(108.4) 
ALA 101.2 
(37.9) 
112.4  
(61.5) 
50.1  
(63.0) 
40.8  
(48.3) 
40.7  
(42.8) 
27.7   
(18.1) 
ARA 4.5 (2.1) 13.0 (5.7) 14.1 (7.1) 15.0 (5.3) 14.3 (6.5) 14.5 (7.1) 
EPA 0.6 (1.6) 1.3 (2.3) 1.1 (1.1) 2.1 (1.5) 1.8 (1.1) 1.4 (1.1) 
DHA 4.2 (2) 11.6 (6.9) 11.4 (7.7) 11.6 (5.9) 10.7 (6.6) 10.6 (6.8) 
Metabolizable intakes (i.e. parenteral intake and absorbed enteral intake) 
LA 665.0 
(248.1) 
772.2 
(377.7) 
409.0 
(385.9) 
324.6 
(297.2) 
317.7 
(236.8) 
269.2 
(101.2) 
ALA 100.8 
(39.3) 
110.5 
(62.4) 
47.9   
(63.6) 
35.3   
(48.0) 
33.6   
(42.2) 
25.5   
(16.6) 
ARA 3.9 (1.7) 10.8 (4.3) 11.3 (5.7) 11.1 (4.7) 11.6 (5.1) 12.4 (6.5) 
EPA 0.2 (0.4) 1.0 (1.8) 0.9 (0.9) 1.6 (1.2) 1.4 (0.9) 1.1 (0.9) 
DHA 3.7 (1.7) 9.7 (5.4) 9.3 (6.1) 9.4 (4.7) 8.7 (5) 8.8 (5.2) 
Available for accretion (metabolizable intake and endogenously synthesized values) 
ARA 14.5 (3.4) 27.4 (10.3) 29.6 (12.7) 32.0 (10.1) 33.4 (9.8) 34.8 (10.8) 
Deficit1 
 
-198.6  
(2.6) 
-185.3 
(10.5) 
-183.1 
(12.6) 
-180.1 
(10.0) 
-178.7 
(10.1) 
-177.5 
(10.9) 
DHA 8.1 (2.2) 17.1 (7.2) 17.6 (8.0) 18.5 (6.5) 18.6 (6.9) 19.0 (7.2) 
27 
 
Deficit1 -36.9 (2.3) -27.9 (7.2) .27.3 (8.0) -26.5 (6.8) -26.4 (6.9) -26.0 (6.8) 
1 Mean deficit compared to estimated in utero accretion rates of 212 mg/kg/day for ARA and 579 
45 mg/kg/day for DHA [2] 580 
 581 
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Table 4. Mean (SD) whole-blood omega-6 and omega-3 PUFAs at 6 weeks and mean (SD) 599 
intakes of LA, ARA, ALA, EPA and DHA over the study of the 17 infants 600 
Fatty Acid % Total fatty acids Mean intake (mg/kg/day) 
LA 8.79 (1.46) 474.5 (122.0) 
18:3n-6 0.30 (0.06)   
20:2n-6 0.36 (0.06)  
20:3n-6 2.22 (0.29)  
ARA 16.74 (1.36) 12.6 (4.4)* 
22:4n-6 3.21 (0.22)  
22:5n-6 1.36 (0.14)  
ΣΝ-6 32.97 (2.72)  
ALA 0.13 (0.05)  80.8 (79.0) 
EPA 0.46 (0.11)  1.4 (0.6)* 
22:5n-3 1.23 (0.24)    
DHA 3.88 (0.82) 10.0 (6.0)* 
ΣN-3 5.70 (0.92)  
Omega-6:omega-3 5.8 (1.2)  
 * indicates significant correlation. ARA: r = 0.568, p = 0.002; EPA: r = 0.572, p = 0.016; 601 
DHA: r = 0.704, p = 0.002. 602 
 603 
